Edition:
United States

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

27.20USD
16 Feb 2018
Change (% chg)

$0.11 (+0.41%)
Prev Close
$27.09
Open
$27.10
Day's High
$27.48
Day's Low
$27.09
Volume
1,641,086
Avg. Vol
2,104,367
52-wk High
$29.92
52-wk Low
$23.30

Chart for

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $37,350.92
Shares Outstanding(Mil.): 1,373.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 46.02 17.27
EPS (TTM): -- -- --
ROI: -- 9.08 35.43
ROE: -- 13.32 17.10

4th Circuit upholds $18.5 mln mesh verdict against Boston Scientific

A federal appeals court on Tuesday upheld a 2014 verdict ordering Boston Scientific Corp to pay four women a total of $18.5 million for injuries caused by the company's transvaginal mesh devices.

Feb 06 2018

Boston Scientific forecast disappoints, eyes M&As

Boston Scientific Corp forecast full-year earnings largely below Wall Street estimate and the medical device maker said it would likely do three or four acquisitions in the next 18 months.

Feb 01 2018

UPDATE 2-Boston Scientific forecast disappoints, eyes M&As

* Shares fall 1.7 pct (Adds conference call details, analysts comments, updates shares)

Feb 01 2018

CORRECTED-UPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates

Feb 1 Boston Scientific Corp on Thursday forecast better-than-expected 2018 revenue after the medical device maker's fourth-quarter sales beat Wall Street estimates on higher sales in its cardiac rhythm management unit.

Feb 01 2018

Boston Scientific posts quarterly loss due to tax charge

Feb 1 Medical device maker Boston Scientific Corp posted a quarterly loss versus a year-ago profit as it incurred a $842 million charge due to changes in the U.S. tax law.

Feb 01 2018

BRIEF-Boston Scientific Reports Q4 Adjusted Earnings Per Share $0.34

* BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017

Feb 01 2018

BRIEF-Boston Scientific Announces Investment And Acquisition Option Agreement With Millipede, Inc.

* BOSTON SCIENTIFIC ANNOUNCES INVESTMENT AND ACQUISITION OPTION AGREEMENT WITH MILLIPEDE, INC.

Jan 24 2018

BRIEF-Boston Scientific Receives U.S. FDA Approval For Spectra Wavewriter Spinal Cord Stimulator System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR SPECTRA WAVEWRITER™ SPINAL CORD STIMULATOR SYSTEM Source text for Eikon: Further company coverage:

Jan 11 2018

BRIEF-Boston Scientific Announces Preliminary Unaudited Sales For Q4 and FY17

* BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017

Jan 09 2018

Boston Scientific loses bid to toss whistleblowers' billing claims

A federal judge has rejected a Boston Scientific Corp unit's bid to dismiss part of a lawsuit alleging it submitted false claims to Medicare for replacement parts for an implantable spinal cord stimulator used to treat chronic pain.

Dec 18 2017

Competitors

Earnings vs. Estimates